BIOMARIN PHARMACEUTICAL INC (BMRN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350M 700M 1.1B Q3 '24: 745.7M Q4 '24: 747.3M Q1 '25: 745.1M Q2 '25: 825.4M Q3 '25: 776.1M Q4 '25: 874.6M Q1 '26: 766.2M Q2 '26: 989.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 300M 600M 900M Q3 '24: 557.3M Q4 '24: 611.2M Q1 '25: 593.6M Q2 '25: 675.3M Q3 '25: 636M Q4 '25: 598.9M Q1 '26: 571.2M Q2 '26: 786.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-100M 0 100M 200M 300M Q3 '24: 113.9M Q4 '24: 161.4M Q1 '25: 223.9M Q2 '25: 276.9M Q3 '25: -46.7M Q4 '25: -44.6M Q1 '26: 129.6M Q2 '26: 110.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-90M 0 90M 180M 270M Q3 '24: 106.1M Q4 '24: 124.9M Q1 '25: 185.7M Q2 '25: 240.5M Q3 '25: -30.7M Q4 '25: -46.6M Q1 '26: 105.5M Q2 '26: 44.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 100M 200M 300M Q3 '24: 188.5M Q4 '24: 136.1M Q1 '25: 151.6M Q2 '25: 150.1M Q3 '25: 140.1M Q4 '25: 275.7M Q1 '26: 195M Q2 '26: 202.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

0 150M 300M 450M Q3 '24: 221.5M Q4 '24: 185.6M Q1 '25: 174.4M Q2 '25: 185.3M Q3 '25: 368.7M Q4 '25: 99.6M Q1 '26: 220.7M Q2 '26: 168.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

0 150M 300M 450M Q3 '24: 203M Q4 '24: 166.1M Q1 '25: 157.6M Q2 '25: 168.2M Q3 '25: 340.2M Q4 '25: 58.9M Q1 '26: 199.7M Q2 '26: 139.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '24: 199.3M Q2 '24: 200.5M Q3 '24: 197.1M Q1 '25: 196.5M Q2 '25: 197.1M Q3 '25: 192M Q1 '26: 197.7M Q2 '26: 194.5M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 1.50 3.00 4.50 Q3 '24: 1.66 Q4 '24: 2.21 Q1 '25: 2.70 Q2 '25: 3.38 Q3 '25: 2.67 Q4 '25: 1.80 Q1 '26: 1.39 Q2 '26: 0.39 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.